Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
22 August 2024 - 10:00PM
UK Regulatory
Zealand Pharma Increases its Share Capital as a Consequence of
Exercise of Employee Warrants
Company announcement – No. 41 / 2024
Zealand Pharma Increases its Share Capital as a
Consequence of Exercise of Employee Warrants
Copenhagen, Denmark, August 22, 2024
– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
20 04 50 78), a Copenhagen-based biotechnology company focused on
the discovery and development of innovative peptide-based
medicines, has increased its share capital by a nominal amount of
DKK 13,000 divided into 13,000 new shares with a nominal value of
DKK 1 each. The increase is a consequence of the exercise of
warrants granted under two of Zealand Pharma's employee
warrant programs.
Employee warrant programs are part of Zealand Pharma’s incentive
scheme, and each warrant gives the owner the right to subscribe for
one newly issued Zealand Pharma share at a prespecified price, the
exercise price, in specific predefined time periods before
expiration. For a more detailed description of Zealand Pharma’s
warrant programs, see the company’s Articles of Association, which
are available on the website: www.zealandpharma.com.
The exercise price was DKK 224.40 per share for 3,000 of new
shares under one employee warrant program and DKK 224.40 per share
as well for 10,000 of new shares related to another employee
warrant program. The total proceeds to Zealand from the capital
increase amount to DKK 2,917,200.00.
The new shares give rights to dividend and other rights from the
time of the warrant holder's exercise notice. Each new share
carries one vote at Zealand Pharma’s general meetings. Zealand
Pharma has only one class of shares.
The new shares will be listed on Nasdaq Copenhagen after
registration of the capital increase with the Danish Business
Authority. Following registration of the new shares, the share
capital of Zealand Pharma will be nominal DKK 71,013,761 divided
into 71,013,761 shares with a nominal value of DKK 1 each.
A full copy of the amended Articles of Association can be found
at https://www.zealandpharma.com once registered with the Danish
Business Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is
a biotechnology company focused on the discovery and development of
peptide-based medicines. More than 10 drug candidates invented by
Zealand have advanced into clinical development, of which two have
reached the market and three candidates are in late-stage
development. The company has development partnerships with a number
of blue-chip pharma companies as well as commercial partnerships
for its marketed products.
Zealand was founded in 1998 and is headquartered
in Copenhagen, Denmark, with a presence in the U.S. that includes
Boston. For more information about Zealand’s business and
activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate
Communications
Zealand Pharma
Email: AKrassowska@zealandpharma.com
Adam Lange
Investor Relations Officer
Zealand Pharma
Email: ALange@zealandpharma.com
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
